A Phase 3 interventional study of pregabalin (Lyrica) in HIV-1 Infection and Neuropathic Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 29 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.
Among the 50 studies testing pregabalin in Neuralgia, this one is the 11th largest by enrollment, is one of 4 that started in 2010, is one of 18 in phase 3, and was the 22nd registered.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:
Moumtzidou Maria Aikaterini · Sites in Greece
Ages 18+ · Women only
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–75
Helsinki University Central Hospital · Sites in Finland
Ages 18–75
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 19 · Phase 4 12
First in 2002; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 217 is above the median of 52 across 832 interventional studies indexed under Neuralgia.
Median enrollment 109 across the 50 interventional studies. Of the 35 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
25 studies in Neuralgia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 25 studies in Neuralgia by Viatris Inc., this one is the 7th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2010, is one of 8 in phase 3, and was the 15th registered.
Viatris Inc.’s Neuralgia studies by the year they started, since 2004.
2 of the studies testing pregabalin in Neuralgia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
| NCT07880223Moumtzidou Maria AikateriniComparison of Two Postoperative Care Strategies After Breast Surgery | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies testing pregabalin in Neuralgia, from their registry updates:
Among Viatris Inc.’s 25 in Neuralgia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study examines the safety of pregabalin over a 6 month period in patients with neuropathic pain associated with HIV infection as an extension of another trial that tests the efficacy of pregabalin.
The parent double blind study was stopped at interim analysis due to lack of efficacy and therefore this open label extension study was also terminated simultaneously on April 2, 2012; the termination was unrelated to any safety findings that could impact patient health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with painful distal sensory polyneuropathy (DSP) interested in treatment based on investigator's clinical judgment.
Subjects who had acceptable tolerability of study drug in A0081244.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pregabalin (Lyrica)
150 mg-600 mg/day (twice daily)
Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to 30 days after last dose of study treatment
Number of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire
WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a Human Immunodeficiency Virus (HIV) neuropathy pain. Number of participants who responded "Yes/No" to Question 1: Are you currently employed (working for pay)? are reported.
Time frame: Baseline, Week 24
Absenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire
WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a HIV neuropathy pain. Question 2 and 3 assesses absenteeism as: Hours of work missed in past 7 days due to leg/foot pain or other reason, respectively. Question 4 assesses presenteeism as: Hours of work performed in past 7 days.
Time frame: Baseline, Week 24
Productivity and Activity Impairment Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire
WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a HIV neuropathy pain. Question 5 and 6 assesses: How much leg/foot pain affect productivity and daily activity, respectively in past 7 days? on 11-point scale, where 0 (not affected/no impairment) to 10 (completely affected/impaired).
Time frame: Baseline, Week 24
36-Item Short-Form Health Survey (SF-36)
SF-36 is a standardized survey evaluating 8 domains of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). Two summary scores include Physical Component (Ph C) and Mental Component (Mn C). The score for a section is an average of the individual question scores. Score range for domain scores and summary scores: 0-100 (100=highest level of functioning).
Time frame: Baseline, Week 24
Visual Analogue Scale for Pain (VAS-pain)
Participants rated the severity of HIV neuropathy pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Time frame: Baseline, Week 4, 8, 12, 16, 20, 24
Number of Participants With Categorical Scores on Patient Global Impression of Change (PGI-C)
PGI-C: participant rated instrument to measure participant's change in overall status since the start of the study, on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Number of participants in each category are reported.
Time frame: Week 24
Number of Participants With Response to Sheehan-Suicidality Tracking Scale (S-STS) Mapped to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories
S-STS:8-item clinician/participant administered prospective rating scale to assess TE suicidal(Su) ideation(ID),behavior(BHV).Items 1a,2-6,7a,8 scored on 5-point Likert scale 0(not at all) to 4(extremely). Items 1,1b,7 require yes/no response. S-STS total score range 0-30. Lower score=reduced Su tendency. Responses on S-STS were mapped to Columbia Classification Algorithm of Suicide Assessment(C-CASA) as 1:Completed Su; 2: Su attempt; 3: Preparatory acts; 4: Su ID; 5: Self-injurious (SI) BHV, intent unknown; 6: Not enough information; 7: SI BHV, no Su intent; 8: Other, no deliberate self harm.
Time frame: Baseline up to Week 25
Number of Participants With Response to Patient Health Questionnaire-8 (PHQ-8)
PHQ-8: 8-item self-administered validated subset of PHQ-9, which comprises first 8 items of measure. Participant rated "Over past 2 weeks, how often bothered by any of following problems?": little interest in doing things(1); feeling down(2); trouble falling or staying asleep/sleeping too much(3); feeling tired(4); poor appetite/overeating(5); feeling bad about self(6); trouble concentrating(7); moving or speaking slowly or being so fidgety/moving around more than usual(8). Each item scored on scale of 0(not at all)-3(nearly every day). Total score range: 0-24, higher score=greater severity.
Time frame: Baseline
Following completion of Visit 9 (Day 57) of double-blind trial A0081244 (NCT01049217), participants who met eligibility criteria initiated open-label treatment in the current trial A0081251 (NCT01145417).
| Milestone | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| Started | 108 | 109 |
| Completed | 67 | 62 |
| Not completed | 41 | 47 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Study terminated by sponsor | 35 | 43 |
| Withdrew: Other | 1 | 0 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| participants | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| AEs | 67 | 70 |
| SAEs | 4 | 3 |
WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a Human Immunodeficiency Virus (HIV) neuropathy pain. Number of participants who responded "Yes/No" to Question 1: Are you currently employed (working for pay)? are reported.
| participants | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| Baseline, employed (n=52,51) | 12 | 11 |
| Baseline, unemployed (n=52,51) | 40 | 40 |
| Week 24, employed (n=103,104) | 35 | 27 |
| Week 24, unemployed (n=103,104) | 68 | 77 |
WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a HIV neuropathy pain. Question 2 and 3 assesses absenteeism as: Hours of work missed in past 7 days due to leg/foot pain or other reason, respectively. Question 4 assesses presenteeism as: Hours of work performed in past 7 days.
| hours | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| Baseline, hours missed,leg/foot pain (n=12,11) | 2.25 ± 6.877 | 0.82 ± 2.401 |
| Baseline, hours missed,other reason (n=12,11) | 3.42 ± 6.501 | 0.91 ± 1.700 |
| Baseline, hours worked (n=12,11) | 35.58 ± 15.163 | 30.36 ± 18.112 |
| Week 24, hours missed,leg/foot pain (n=35,28) | 2.17 ± 4.956 | 2.32 ± 8.533 |
| Week 24, hours missed,other reason (n=35,28) | 9.20 ± 21.604 | 7.71 ± 14.976 |
| Week 24, hours worked (n=35,28) | 41.51 ± 20.034 | 34.86 ± 21.329 |
WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a HIV neuropathy pain. Question 5 and 6 assesses: How much leg/foot pain affect productivity and daily activity, respectively in past 7 days? on 11-point scale, where 0 (not affected/no impairment) to 10 (completely affected/impaired).
| Units on a scale | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| Baseline, productivity affected (n=12,10) | 4.42 ± 2.843 | 2.40 ± 2.716 |
| Baseline, daily activity affected (n=52,51) | 3.48 ± 2.846 | 3.47 ± 2.935 |
| Week 24, productivity affected (n=35,29) | 2.17 ± 1.917 | 2.24 ± 2.415 |
| Week 24, daily activity affected (n=103,104) | 2.51 ± 2.330 | 2.72 ± 2.653 |
SF-36 is a standardized survey evaluating 8 domains of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). Two summary scores include Physical Component (Ph C) and Mental Component (Mn C). The score for a section is an average of the individual question scores. Score range for domain scores and summary scores: 0-100 (100=highest level of functioning).
| Units on a scale | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| Baseline: Ph Fn (n=51,53) | 73.14 ± 22.671 | 75.47 ± 22.729 |
| Baseline: R-P (n=51,53) | 75.49 ± 22.873 | 71.93 ± 27.616 |
| Baseline: BP (n=51,53) | 68.86 ± 20.430 | 68.87 ± 26.010 |
| Baseline: GH (n=51,53) | 72.25 ± 20.369 | 68.79 ± 20.411 |
| Baseline: Ph C (n=51,53) | 47.68 ± 7.268 | 46.85 ± 9.578 |
| Baseline: Vit (n=51,53) | 71.57 ± 19.418 | 73.11 ± 17.660 |
| Baseline: So Fn (n=51,53) | 78.92 ± 18.113 | 82.08 ± 18.911 |
| Baseline: R-E (n=51,53) | 81.05 ± 20.075 | 79.87 ± 23.367 |
| Baseline: MnH (n=51,53) | 76.27 ± 18.079 | 80.00 ± 15.411 |
| Baseline: Mn C (n=51,53) | 51.41 ± 8.915 | 52.71 ± 7.763 |
| Week 24: Ph Fn (n=103,104) | 70.34 ± 27.594 | 75.24 ± 25.086 |
| Week 24: R-P (n=103,104) | 71.18 ± 24.927 | 72.96 ± 26.680 |
| Week 24: BP (n=102,104) | 69.57 ± 22.550 | 72.19 ± 23.033 |
| Week 24: GH (n=103,104) | 73.14 ± 19.933 | 71.31 ± 19.879 |
| Week 24: Ph C (n=102,104) | 47.28 ± 8.770 | 48.48 ± 8.634 |
| Week 24: Vit (n=103,104) | 68.51 ± 18.502 | 66.29 ± 20.039 |
| Week 24: So Fn (n=103,104) | 79.98 ± 20.883 | 81.85 ± 20.304 |
| Week 24: R-E (n=103,104) | 74.19 ± 27.029 | 75.80 ± 25.640 |
| Week 24: MnH (n=103,104) | 76.21 ± 18.196 | 75.77 ± 18.588 |
| Week 24: Mn C (n=102,104) | 50.15 ± 10.394 | 49.72 ± 9.884 |
Participants rated the severity of HIV neuropathy pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
| millimeter (mm) | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| Baseline (n=107,108) | 40.6 ± 26.55 | 40.7 ± 26.57 |
| Week 4 (n=106,106) | 33.1 ± 25.14 | 33.1 ± 27.11 |
| Week 8 (n=100,101) | 27.4 ± 21.01 | 27.8 ± 24.25 |
| Week 12 (n=89,88) | 24.1 ± 22.41 | 23.8 ± 23.45 |
| Week 16 (n=85,81) | 22.6 ± 20.82 | 22.6 ± 25.32 |
| Week 20 (n=72,67) | 17.2 ± 19.18 | 17.7 ± 22.78 |
| Week 24 (n=103,104) | 22.2 ± 22.54 | 23.7 ± 23.94 |
PGI-C: participant rated instrument to measure participant's change in overall status since the start of the study, on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Number of participants in each category are reported.
| participants | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| Very Much Improved | 41 | 37 |
| Much Improved | 43 | 47 |
| Minimally Improved | 16 | 16 |
| No Change | 2 | 3 |
| Minimally Worse | 1 | 0 |
| Much Worse | 0 | 1 |
| Very Much Worse | 0 | 0 |
S-STS:8-item clinician/participant administered prospective rating scale to assess TE suicidal(Su) ideation(ID),behavior(BHV).Items 1a,2-6,7a,8 scored on 5-point Likert scale 0(not at all) to 4(extremely). Items 1,1b,7 require yes/no response. S-STS total score range 0-30. Lower score=reduced Su tendency. Responses on S-STS were mapped to Columbia Classification Algorithm of Suicide Assessment(C-CASA) as 1:Completed Su; 2: Su attempt; 3: Preparatory acts; 4: Su ID; 5: Self-injurious (SI) BHV, intent unknown; 6: Not enough information; 7: SI BHV, no Su intent; 8: Other, no deliberate self harm.
| participants | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| Suicide attempt: 2 | 0 | 1 |
| Preparatory acts toward suicidal behavior: 3 | 0 | 1 |
| Suicidal ideation: 4 | 4 | 9 |
PHQ-8: 8-item self-administered validated subset of PHQ-9, which comprises first 8 items of measure. Participant rated "Over past 2 weeks, how often bothered by any of following problems?": little interest in doing things(1); feeling down(2); trouble falling or staying asleep/sleeping too much(3); feeling tired(4); poor appetite/overeating(5); feeling bad about self(6); trouble concentrating(7); moving or speaking slowly or being so fidgety/moving around more than usual(8). Each item scored on scale of 0(not at all)-3(nearly every day). Total score range: 0-24, higher score=greater severity.
| participants | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| Little interest in things: Not at All | 59 | 67 |
| Little interest in things: Several Days | 31 | 25 |
| Little interest in things: More Than Half the Days | 14 | 9 |
| Little interest in things: Nearly Every Day | 3 | 7 |
| Feeling down: Not at All | 84 | 79 |
| Feeling down: Several Days | 18 | 21 |
| Feeling down: More Than Half the Days | 5 | 6 |
| Feeling down: Nearly Every Day | 0 | 2 |
| Trouble with sleep: Not at All | 57 | 59 |
| Trouble with sleep: Several Days | 33 | 40 |
| Trouble with sleep: More Than Half the Days | 14 | 4 |
| Trouble with sleep: Nearly Every Day | 3 | 5 |
| Feeling tired: Not at All | 52 | 53 |
| Feeling tired: Several Days | 43 | 40 |
| Feeling tired: More Than Half the Days | 12 | 14 |
| Feeling tired: Nearly Every Day | 0 | 1 |
| Poor appetite/overeating: Not at All | 75 | 71 |
| Poor appetite/overeating: Several Days | 24 | 26 |
| Poor appetite/overeating: More Than Half the Days | 5 | 5 |
| Poor appetite/overeating: Nearly Every Day | 3 | 6 |
| Feeling bad about self: Not at All | 92 | 88 |
| Feeling bad about self: Several Days | 12 | 13 |
| Feeling bad about self: More Than Half the Days | 2 | 3 |
| Feeling bad about self: Nearly Every Day | 1 | 4 |
| Trouble concentrating: Not at All | 79 | 84 |
| Trouble concentrating: Several Days | 23 | 20 |
| Trouble concentrating: More Than Half the Days | 2 | 3 |
| Trouble concentrating: Nearly Every Day | 3 | 1 |
| Move or speak slow/fidgety: Not at All | 87 | 86 |
| Move or speak slow/fidgety: Several Days | 18 | 16 |
| Move or speak slow/fidget: More Than Half the Days | 0 | 3 |
| Move or speak slow/fidgety: Nearly Every Day | 2 | 3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin-Pregabalin | — | 4/108 (3.7%) | 35/108 (32.4%) |
| Placebo-Pregabalin | — | 3/109 (2.8%) | 50/109 (45.9%) |
| Event | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| CellulitisInfections and infestations | 1/108 | 0/109 |
| HIV infectionInfections and infestations | 1/108 | 0/109 |
| Muscle strainInjury, poisoning and procedural complications | 1/108 | 0/109 |
| Transient ischaemic attackNervous system disorders | 1/108 | 0/109 |
| Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders | 0/108 | 1/109 |
| GastroenteritisInfections and infestations | 0/108 | 1/109 |
| Facial bones fractureInjury, poisoning and procedural complications | 0/108 | 1/109 |
| Kaposi's sarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/108 | 1/109 |
| Event | Pregabalin-Pregabalin | Placebo-Pregabalin |
|---|---|---|
| DizzinessNervous system disorders | 10/108 | 19/109 |
| SomnolenceNervous system disorders | 9/108 | 14/109 |
| HeadacheNervous system disorders | 5/108 | 8/109 |
| InfluenzaInfections and infestations | 5/108 | 7/109 |
| Back painMusculoskeletal and connective tissue disorders | 6/108 | 2/109 |
| Oedema peripheralGeneral disorders | 2/108 | 6/109 |
| PharyngitisInfections and infestations | 2/108 | 6/109 |
| Age, Continuous(years) | Pregabalin-Pregabalin | Placebo-Pregabalin | Total |
|---|---|---|---|
| Mean | 42.4 ± 8.8 | 43.5 ± 7.9 | 42.9 ± 8.4 |
| Sex: Female, Male(Participants) | Pregabalin-Pregabalin | Placebo-Pregabalin | Total |
|---|---|---|---|
| Female | 71 | 68 | 139 |
| Male | 37 | 41 | 78 |
The record gives a start of Jul 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →